Is Brand Meditech profitable?

Yes but shrinking. Trailing 12-month net profit was about $1.21M with EPS around $0.11 on revenue of $25.49M, though revenue fell 2.7% in the most recent tracked period as of July 4, 2026, per stockanalysis.com.

When is Brand Meditech's IPO date?

Brand Meditech filed its F-1 with the SEC on December 11, 2025 to list on Nasdaq under ticker AED, offering 900,000 shares at $7 to $9 each. As of July 4, 2026 the deal remained unpriced with no set listing date, per stockanalysis.com.

Who owns Brand Meditech?

Brand Meditech Limited is a Cayman Islands holding company with subsidiaries BM HK in Hong Kong and Niche Medical in Xuzhou, mainland China, filed December 11, 2025. No institutional VC or PE backing was disclosed in IPO filing coverage.

Could AI replace Brand Meditech's business?

Its core physical distribution, installation and maintenance work is largely AI-insulated, but its imaging post-processing software brands Prim and iMRIPlus sit in a segment where AI-native diagnostic tools could erode differentiation, per the December 10, 2025 IPO filing summary.

Who is Brand Meditech's biggest competitor?

Mindray dominates Chinese hospital procurement of monitors, defibrillators and ventilators through government-tender preference, directly overlapping Brand Meditech's core distributed categories, as of a July 2026 industry market-tracking source.

Is Brand Meditech a safe company to join as an employee?

SEC filings put headcount at just 24 employees as of December 10, 2025, against $25.49M in trailing revenue, while a separate vendor page claims over 100 staff, an unresolved discrepancy alongside a still-unpriced IPO as of July 2026.

No grouping · acquisition pending · Hong Kong

Brand Meditech Limited

Hong Kong distributor of imaging and medical devices, filing to list on Nasdaq as AED.

Protection under test

Assessed 29 July 2026 · Evidence as of 29 July 2026

Something worth protecting exists and is being tested right now.

On the recordSince 29 July 2026 · Checkable from Q3-Q4 2026 · Every call on the record Checkpoint: IPO pricing and Nasdaq listing, plus FY2026 audited revenue confirming whether the decline continues

The call

A shrinking, profitable distributor with a tiny unproven device arm, seeking a Nasdaq listing with no named threat yet visibly taking its business.

Brand Meditech buys medical devices from manufacturers and sells them to hospitals and clinics in its region, making about 10% profit on $25.5 million in sales. The distribution part is easy for anyone to copy, since it just requires connections and logistics, not secret technology; any big medical company or local competitor could do what Brand Meditech does. The company is betting its future on Niche Medical, a small hardware unit working on devices like portable X-ray machines, but these products are still years away from real revenue and may never work out. What matters next: whether the company can stop losing sales in its core business, whether the new hardware products actually get approved and customers buy them, and whether the stock price stays up after it goes public, since small Chinese companies listed this way have historically struggled.

Why

AI pressure: None apparent. AI diagnostic or imaging software isn't named as a factor; the business is device distribution and hardware, not software. Could AI do the core job? Only partly.

Bigger players: Larger medical device manufacturers and regional distributors. Any manufacturer or rival distributor can copy its regional channel role, and revenue already fell 2.7% before any named competitor moved. Could a giant copy it? Yes, easily.

What protects it. A small, profitable niche in Hong Kong and mainland China distribution that hasn't attracted bigger players yet.

What would change this call

Nasdaq IPO priced or withdrawn by end of 2026. Shows whether the micro-cap listing structure holds together as planned.
FY2026 audited revenue figure published. Confirms whether the -2.7% distribution revenue decline continues or reverses.
Mainland China regulatory clearance granted for Niche Medical's AED or portable X-ray. Would show the proprietary-device arm becoming a real revenue contributor.

Key numbers

LTM revenue $25.5M, down 2.7% (Jul 4, 2026)
EBITDA margin ~10.5%-11.8%, $2.67M-$3.09M (n.d.)
IPO size ~900,000 shares at $7-$9, ~$7.2M-$8.1M raised (Dec 11, 2025)

Named risks

IPO deal remains unpriced with no set date as of July 2026, could be delayed or withdrawn. Severity: high
Core revenue declining 2.7% with no structural moat in commodity distribution business. Severity: high
Headcount discrepancy: 24 employees per SEC filings vs over 100 claimed by vendor page. Severity: medium
Niche Medical proprietary devices (AED, portable X-ray) still in testing, years from material revenue. Severity: medium
Micro-cap China/HK to Nasdaq listings via boutique underwriters historically struggle to hold IPO valuation. Severity: high

Rivals, as read in July 2026

Rival	Direction	Evidence
Mindray	losing to	Dominates Chinese hospital tenders for monitors, defibrillators, ventilators, per Jul 2026 market source
Manufacturers going direct (e.g. Corscience)	contesting	No structural barrier stops device makers bypassing distributor role, per Dec 2025 filing analysis
Domestic Chinese distributors	contesting	Regional channel role easily replicated by competing resellers, per Dec 2025 filing summary

Questions people ask

Is Brand Meditech profitable?: Yes but shrinking. Trailing 12-month net profit was about $1.21M with EPS around $0.11 on revenue of $25.49M, though revenue fell 2.7% in the most recent tracked period as of July 4, 2026, per stockanalysis.com.
When is Brand Meditech's IPO date?: Brand Meditech filed its F-1 with the SEC on December 11, 2025 to list on Nasdaq under ticker AED, offering 900,000 shares at $7 to $9 each. As of July 4, 2026 the deal remained unpriced with no set listing date, per stockanalysis.com.
Who owns Brand Meditech?: Brand Meditech Limited is a Cayman Islands holding company with subsidiaries BM HK in Hong Kong and Niche Medical in Xuzhou, mainland China, filed December 11, 2025. No institutional VC or PE backing was disclosed in IPO filing coverage.
Could AI replace Brand Meditech's business?: Its core physical distribution, installation and maintenance work is largely AI-insulated, but its imaging post-processing software brands Prim and iMRIPlus sit in a segment where AI-native diagnostic tools could erode differentiation, per the December 10, 2025 IPO filing summary.
Who is Brand Meditech's biggest competitor?: Mindray dominates Chinese hospital procurement of monitors, defibrillators and ventilators through government-tender preference, directly overlapping Brand Meditech's core distributed categories, as of a July 2026 industry market-tracking source.
Is Brand Meditech a safe company to join as an employee?: SEC filings put headcount at just 24 employees as of December 10, 2025, against $25.49M in trailing revenue, while a separate vendor page claims over 100 staff, an unresolved discrepancy alongside a still-unpriced IPO as of July 2026.

Timeline

2026-07-04IPO remains unpriced, exact listing date still unset per stockanalysis.com
2026-03-17MarketWatch pre-IPO profile lists proceeds earmarked for R&D and expansion
2025-12-11Brand Meditech files F-1 with SEC for Nasdaq listing under ticker AED
2025-12-11Offering set at 900,000 Class A shares, $7 to $9 price range, Maxim Group sole bookrunner
2025-12-10Company profile lists 24 employees and 2003 founding year, conflicting with 1993 vendor claim
2025-03-31FY2025 year end: BM HK generates large majority of revenue, Niche Medical nascent
1993BM HK reportedly established in Hong Kong as medical equipment importer, per vendor source

Revision history

29 July 2026

First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.

In the same band

Ford Motor Whirlpool Solventum

More companies protection under test →

Sources